Are You Interested in Starting Your Own Health Related Home Based Business? Please Click Here to Find Out How!

Forest Laboratories, Inc. (NYSE: FRX) presented positive Phase III data of a once-daily extended-release formulation of Namenda(R) (memantine HCl) at the 2008 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD).

More: continued here

Are You Interested in Starting Your Own Health Related Home Based Business? Please Click Here to Find Out How!

Results from clinical trials of three potential Alzheimer’s therapies raise hope for new and better treatments of the disease, according to data reported today at the 2008 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD 2008) in Chicago. A related study showed that taking antidementia drugs appears to have a positive impact on extending lifespan in those with Alzheimer’s.

More: continued here

Are You Interested in Starting Your Own Health Related Home Based Business? Please Click Here to Find Out How!

Memory Pharmaceuticals Corp. (Nasdaq: MEMY) presented preclinical data for MEM 68626, its lead 5-HT6 antagonist drug candidate, at the 2008 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD) in Chicago. The results demonstrate that MEM 68626 is effective in models of cognition that are considered predictive of efficacy in Alzheimer’s disease and mild cognitive impairment (MCI).

More: continued here

Are You Interested in Starting Your Own Health Related Home Based Business? Please Click Here to Find Out How!

Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) have presented detailed results from the companies’ 18-month Phase 2 study of bapineuzumab (AAB-001) in patients with mild to moderate Alzheimer’s disease at the Alzheimer’s Association’s International Conference on Alzheimer’s Disease 2008 in Chicago, Illinois. As previously announced, in the study, bapineuzumab appeared to have an acceptable safety profile and clinical activity in treating Alzheimer’s disease.

More: continued here

Are You Interested in Starting Your Own Health Related Home Based Business? Please Click Here to Find Out How!

NewYork-Presbyterian Hospital/Weill Cornell Medical Center announced the nine-month interim results of an ongoing Phase II clinical trial of GAMMAGARD Intravenous Immunoglobulin (IGIV) for Alzheimer’s disease at the Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD) in Chicago.

More: continued here

Are You Interested in Starting Your Own Health Related Home Based Business? Please Click Here to Find Out How!

Alzheimer Scotland welcomes the results of this Phase 2 study on a new treatment for dementia. Jim Jackson, Chief Executive at Alzheimer Scotland, said, “The initial results of this trial are exciting: responses are extremely encouraging compared to existing treatments. Effectively targeting the protein tangles that kill brain cells would be a new breakthrough in drugs aimed at improving cognition in people with dementia.

More: continued here

Are You Interested in Starting Your Own Health Related Home Based Business? Please Click Here to Find Out How!

Avid Radiopharmaceuticals presented clinical results on the development of a novel 18F-labeled PET amyloid imaging agent, 18F-AV-45, that may eventually provide a practical approach for routine brain imaging of people at risk for the development of Alzheimer’s disease. At the ICAD meeting in Chicago, Avid presented results of the exploratory IND clinical studies of three novel amyloid plaque imaging agents.

More: continued here

Are You Interested in Starting Your Own Health Related Home Based Business? Please Click Here to Find Out How!

A new drug has been shown to improve the brain function of people with early stage Alzheimer’s disease and reduce a key protein associated with the disease in the spinal fluid, in a small study published in the journal Lancet Neurology and presented at the 2008 Alzheimer’s Association International Conference on Alzheimer’s Disease. The drug, known as PBT2, counteracts the production and build-up of a protein called amyloid-beta that occurs in Alzheimer’s disease.

More: continued here

Are You Interested in Starting Your Own Health Related Home Based Business? Please Click Here to Find Out How!

ANAVEX Life Sciences Corp. (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, presented data from the company’s novel compound, ANAVEX 1-41, targeting Alzheimer’s disease, at the International Conference on Alzheimer’s Disease (ICAD) 2008, Chicago, USA, July 26 to 31, 2008.

More: continued here

Are You Interested in Starting Your Own Health Related Home Based Business? Please Click Here to Find Out How!

Breakthrough genetic research to map all the genes connected to Alzheimer’s, which could lead to more aggressive treatment and a potential cure for the disease, was the focus of a presentation by leading Alzheimer’s researcher Dr. Rudolph Tanzi at the International Conference on Alzheimer’s Disease (ICAD) in Chicago.

More: continued here